Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Benitec Biopharma (BNTC) over the last 6 years, with Q1 2025 value amounting to -$6000.0.

  • Benitec Biopharma's Cash from Investing Activities rose 9664.8% to -$6000.0 in Q1 2025 from the same period last year, while for Jun 2025 it was -$18000.0, marking a year-over-year increase of 8994.41%. This contributed to the annual value of -$18000.0 for FY2025, which is 8994.41% up from last year.
  • As of Q1 2025, Benitec Biopharma's Cash from Investing Activities stood at -$6000.0, which was up 9664.8% from -$12000.0 recorded in Q4 2024.
  • Over the past 5 years, Benitec Biopharma's Cash from Investing Activities peaked at $141000.0 during Q2 2021, and registered a low of -$179000.0 during Q1 2024.
  • Over the past 4 years, Benitec Biopharma's median Cash from Investing Activities value was -$12500.0 (recorded in 2022), while the average stood at -$14000.0.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 118461.54% in 2021, then crashed by 10921.99% in 2022.
  • Benitec Biopharma's Cash from Investing Activities (Quarter) stood at $141000.0 in 2021, then tumbled by 109.22% to -$13000.0 in 2022, then grew by 7.69% to -$12000.0 in 2024, then surged by 50.0% to -$6000.0 in 2025.
  • Its Cash from Investing Activities was -$6000.0 in Q1 2025, compared to -$12000.0 in Q4 2024 and -$179000.0 in Q1 2024.